DUBLIN, Jan 27, 2017 /PRNewswire/ --

Research and Markets has announced the addition of the "PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025" report to their offering.

Cardiovascular diseases (CVD), including ischemic heart disease and stroke, are the leading causes of mortality in the world. The term acute coronary syndrome (ACS) applies to a spectrum of acute CVD states that are precipitated by coronary artery occlusion (stenosis) that results in ischemia (a reduction or loss of blood flow to tissue) and the necrosis of myocardial tissue .In the most modern use of the term, ACS strictly refers to a range of ischemic cardiovascular events that includes unstable angina (UA), myocardial infarction (MI) and/or death due to myocardial ischemia.

In general, these ACS events can be viewed as the culmination of coronary artery disease (CAD), the asymptomatic build-up of atherosclerotic plaque on the walls of the coronary arteries. The triggering of an ACS event stemming from UA or MI initiates the acute phase treatment setting where therapeutic interventions are utilized to reverse and prevent the physiochemical processes that lead to coronary stenosis. Whereas, the chronic phase treatment setting involves secondary preventative measures that are used to avoid recurrent ACS events from occurring.

Key Findings

- The main driver of the significant expansion of the ACS market will be the increase in use and physician confidence in the PCSK9 inhibitor class, which will hold four major players by the end of this forecast. Novel lipid lowering therapy, ETC-1002, will also be a major contributor, vying to steal majority of patient shares for the statin intolerant ACS population by the end of this forecast.
- The major global barrier for the ACS market will be the generic erosion of the key antiplatelet therapies, Brilinta and Effient by the end of this forecast. Both drugs will pick up significant momentum in sales prior to patent expiry.
- The dynamics of the ACS market will shift greatly towards solving the atherosclerotic burden associated in ACS from the historical strategy of developing antithrombotic therapies.
- The key market opportunities lie in addressing unmet needs through the development of optimal agents for secondary prevention by controlling lipid levels and repairing the damaged myocardium post myocardial infarction to prevent comorbidities such as heart failure.

Key Topics Covered:

1 Tables & Figures

2 Introduction

3 Disease Overview

4 Epidemiology

5 Disease Management

6 Competitive Assessment

7 Unmet Need and Opportunity

8 Pipeline Assessment

9 Current and Future Players

10 Market Outlook

11 Appendix

Companies Mentioned

• Amgen
• AstraZeneca
• Bristol-Myers Squibb
• Cerenis Therapeutics
• CSL Limited
• Daiichi Sankyo
• Eli Lilly
• Esperion Therapeutics
• GlaxoSmithKline
• Janssen
• The Medicines Company
• Merck & Co.
• Pfizer
• Sanofi

For more information about this report visit http://www.researchandmarkets.com/research/xp79rq/pharmapoint

About Research and Markets
Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Related Links

http://www.researchandmarkets.com

SOURCE Research and Markets